Sector News

Boehringer aims to cut up to 600 jobs in Germany

September 23, 2014
Life sciences
(Reuters) – Drugmaker Boehringer Ingelheim said it plans to cut up to 600 jobs in Germany, citing healthcare budget cuts in the United States and a stricter reimbursement regime in Germany.
The unlisted family-controlled group, which collaborates on diabetes drugs with Eli Lilly, said in a statement on Tuesday the cutbacks were part of a drive to reduce costs in Germany by 15 percent or 450 million euros ($580 million).
The company, which makes stroke prevention pill Pradaxa, plans to cut between 500 and 600 jobs in Germany by the end of 2016, seeking to avoid forced redundancies.
Of its global workforce of 47,500, the group employs about 14,000 in Germany.
(1 US dollar = 0.7759 euro) (Reporting by Ludwig Burger; Editing by David Holmes)

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]